Utility of [18F]-fluoroestradiol (FES) PET/CT with dedicated brain acquisition in differentiating brain metastases from posttreatment change in estrogen receptor-positive breast cancer
A 41-year-old woman presented with recurrent, metastatic, ER-positive invasive ductal carcinoma. The patient had initially presented 10 years prior with a palpable breast lesion. Pathology at the time of initial diagnosis was remarkable for a 7-cm invasive ductal carcinoma with lymphovascular invasion, as well as positive metastatic lymph nodes with evidence of extracapsular extension. Immunohistochemistry demonstrated the tumor to be ER-positive (70%), progesterone receptor-negative, and HER2-positive.